Your browser doesn't support javascript.
loading
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan, Locke J; Casulo, Carla; Allen, Pamela B; Smith, Scott E; Savas, Hatice; Dillehay, Gary L; Karmali, Reem; Pro, Barbara; Kane, Kaitlyn L; Bazzi, Latifa A; Chmiel, Joan S; Palmer, Brett A; Mehta, Jayesh; Gordon, Leo I; Winter, Jane N.
Afiliação
  • Bryan LJ; Division of Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta.
  • Casulo C; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
  • Allen PB; Division of Hematology and Oncology, Emory University, Atlanta, Georgia.
  • Smith SE; Division of Hematology and Oncology, Loyola University Medical Center, Maywood, Illinois.
  • Savas H; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Dillehay GL; Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Karmali R; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Pro B; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Kane KL; Robert H. Lurie Comprehensive Cancer Center, Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Bazzi LA; Robert H. Lurie Comprehensive Cancer Center, Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Chmiel JS; Robert H. Lurie Comprehensive Cancer Center, Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Palmer BA; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Mehta J; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Gordon LI; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Winter JN; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
JAMA Oncol ; 9(5): 683-691, 2023 05 01.
Article em En | MEDLINE | ID: mdl-36928527
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article